Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

632
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
632
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Autoregulation of Blood Flow01:17

Autoregulation of Blood Flow

2.7K
Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
2.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-atom Mo decorated TiO<sub>2</sub> hollow sphere catalyst: Engineering local electric field polarization to boost photocatalytic conversion of diluted CO<sub>2</sub>.

Journal of colloid and interface science·2026
Same author

Structure-guided reprogramming of DELLA turnover for a sustainable Green Revolution in rice.

Nature communications·2026
Same author

Biological Context-Informed and Population-Stratified Strategies Improve Genetic Diagnosis of CCDC22-Related Disorder.

Genetics research·2026
Same author

Identification of Th17 Cell-Associated Biomarkers and Their Potential Regulatory Mechanisms in Chronic Obstructive Pulmonary Disease Through Integrated Bioinformatics Analysis and Machine Learning.

International journal of chronic obstructive pulmonary disease·2026
Same author

IRF-1 Links Cytoskeletal Contraction With Inflammatory Response in mTOR-Inhibited Endothelial Cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Co-occurrence of resistance and virulence plasmids in a bla<sub>NDM-5</sub>-positive Escherichia coli ST602 clone across One Health sectors in China.

Journal of hazardous materials·2026

Related Experiment Video

Updated: Sep 3, 2025

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

9.7K

mTOR contributes to endothelium-dependent vasorelaxation by promoting eNOS expression and preventing eNOS uncoupling.

Yiying Wang1,2, Qiannan Li1,2, Zhiyang Zhang1,2

  • 1Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China.

Communications Biology
|July 22, 2022
PubMed
Summary

Mammalian target of rapamycin (mTOR) inhibitors impair blood vessel function by reducing nitric oxide (NO) production. This study reveals distinct mechanisms for mTORC1 and mTORC2 inhibition impacting endothelial-dependent vasodilatation.

More Related Videos

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography
09:47

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography

Published on: August 12, 2022

3.3K
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

9.9K

Related Experiment Videos

Last Updated: Sep 3, 2025

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

9.7K
Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography
09:47

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography

Published on: August 12, 2022

3.3K
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

9.9K

Area of Science:

  • Vascular Biology
  • Molecular Medicine
  • Cell Signaling

Background:

  • Clinically used mammalian target of rapamycin (mTOR) inhibitors negatively impact endothelial-dependent vasodilatation (EDD).
  • The precise mechanisms underlying this impairment remain unidentified.
  • Endothelial dysfunction contributes to various cardiovascular diseases.

Purpose of the Study:

  • To elucidate the mechanisms by which mTOR inhibition affects endothelial function and nitric oxide (NO) production.
  • To differentiate the roles of mTORC1 and mTORC2 in regulating endothelial-dependent vasodilatation.
  • To identify potential therapeutic targets for restoring EDD in mTOR-inhibited conditions.

Main Methods:

  • Endothelium-specific deletion of Mtor in mice to inhibit both mTOR complexes.
  • Depletion of Raptor or Rictor to selectively disrupt mTORC1 or mTORC2.
  • Measurement of NO levels in mouse serum and endothelial cells (EC).
  • Analysis of eNOS gene expression, KLF2 regulation, MAPK activation, and reactive oxygen species (ROS) generation.

Main Results:

  • Endothelium-specific Mtor inhibition, or disruption of mTORC1/mTORC2, impaired EDD and reduced serum NO.
  • mTORC1 inhibition suppressed eNOS gene expression via impaired p70S6K-mediated KLF2 regulation.
  • mTORC2 inhibition led to excessive ROS generation, eNOS uncoupling, and decreased NO bioavailability through MAPK activation and Nox2 upregulation.
  • Adeno-associated virus-mediated KLF2 overexpression or Nox2 suppression restored EDD in inhibited mice.

Conclusions:

  • mTORC1 and mTORC2 regulate EDD through distinct molecular pathways involving NO production.
  • mTORC1 affects EDD by modulating eNOS expression via KLF2.
  • mTORC2 impacts EDD by promoting oxidative stress and eNOS uncoupling.
  • Targeting KLF2 or Nox2 may offer therapeutic strategies to counteract mTOR inhibitor-induced endothelial dysfunction.